Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Menter, Alan
333  Ergebnisse:
Personensuche X
?
1

Response to letter to the editor "It's time to consider a n..:

Elmets, Craig A. ; Menter, Alan ; Malik, Sameer.
Journal of the American Academy of Dermatology.  90 (2024)  2 - p. e83 , 2024
Link: https://doi.org/10.1016/..
 
?
2

Efficacy of long‐term risankizumab treatment for moderate‐t..:

Strober, Bruce ; Bachelez, Hervé ; Crowley, Jeffrey...
Journal of the European Academy of Dermatology and Venereology.  38 (2024)  5 - p. 864-872 , 2024
Link: https://doi.org/10.1111/..
 
?
3

Summary of Research: Switching Between Adalimumab Reference..:

Menter, Alan
Dermatology and Therapy.  13 (2023)  12 - p. 2929-2932 , 2023
Link: https://doi.org/10.1007/..
 
?
4

Deucravacitinib long-term efficacy with continuous treatmen..:

Lebwohl, Mark ; Warren, Richard B. ; Sofen, Howard...
SKIN The Journal of Cutaneous Medicine.  7 (2023)  2 - p. s118 , 2023
Link: https://doi.org/10.25251..
 
?
5

Deucravacitinib, an oral, selective, allosteric tyrosine ki..:

Bagel, Jerry ; Armstrong, April W. ; Warren, Richard B....
SKIN The Journal of Cutaneous Medicine.  7 (2023)  2 - p. s117 , 2023
Link: https://doi.org/10.25251..
 
?
6

43851 Deucravacitinib Long-term Efficacy With Continuous Tr..:

Lebwohl, Mark ; Warren, Richard B. ; Kircik, Leon...
Journal of the American Academy of Dermatology.  89 (2023)  3 - p. AB35 , 2023
Link: https://doi.org/10.1016/..
 
?
7

Symptom Experience and Content Validity of the Psoriasis Sy..:

Burden, A. David ; Mrowietz, Ulrich ; Skalicky, Anne M....
Dermatology and Therapy.  12 (2022)  6 - p. 1367-1381 , 2022
Link: https://doi.org/10.1007/..
 
?
8

Switching Between Adalimumab Reference Product and BI 69550..:

Menter, Alan ; Cohen, Stanley ; Kay, Jonathan...
American Journal of Clinical Dermatology.  23 (2022)  5 - p. 719-728 , 2022
Link: https://doi.org/10.1007/..
 
?
9

Cryptococcal meningitis associated with interleukin‐17 inhi..:

Driver, Joseph ; Zaayman, Marcus ; Silfvast‐Kaiser, Annika.
Dermatologic Therapy.  , 2022
Link: https://doi.org/10.1111/..
 
?
10

33221 Further clinical outcomes in patients with moderate-t..:

Menter, Alan ; McCabe, Dorothy ; Lang, Benjamin
Journal of the American Academy of Dermatology.  87 (2022)  3 - p. AB61 , 2022
Link: https://doi.org/10.1016/..
 
?
11

Deucravacitinib, an oral, selective tyrosine kinase 2 inhib..:

Bagel, Jerry ; Armstrong, April ; Warren, Richard...
SKIN The Journal of Cutaneous Medicine.  6 (2022)  6 - p. s47 , 2022
Link: https://doi.org/10.25251..
 
?
12

Deucravacitinib long-term efficacy and safety in plaque pso..:

Warren, Richard ; Sofen, Howard ; Imafuku, Shinichi...
SKIN The Journal of Cutaneous Medicine.  6 (2022)  6 - p. s48 , 2022
Link: https://doi.org/10.25251..
 
?
13

Narrative Review of the Emerging Therapeutic Role of Brodal..:

Menter, Alan ; Bhutani, Tina ; Ehst, Benjamin..
Dermatology and Therapy.  12 (2022)  6 - p. 1289-1302 , 2022
Link: https://doi.org/10.1007/..
 
?
14

Pustular Psoriasis: A Narrative Review of Recent Developmen..:

Menter, Alan ; Van Voorhees, Abby S. ; Hsu, Sylvia
Dermatology and Therapy.  11 (2021)  6 - p. 1917-1929 , 2021
Link: https://doi.org/10.1007/..
 
?
15

A Machine Learning-Based Test for Predicting Response to Ps..:

Bagel, Jerry ; Wang, Yipeng ; Montgomery, III, Paul...
SKIN The Journal of Cutaneous Medicine.  5 (2021)  6 - p. 621-638 , 2021
Link: https://doi.org/10.25251..
 
1-15